Maximizing antigen targeting to the proteasome for gene-based vaccines

Molecular Therapy

Volumn 10, Issue 3, 2004, Pages 432-446

  Andersson, Helen A ^a,b   Barry, Michael A ^a,b,c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Rice University   (United States)

Author keywords

Genetic immunization; Proteasome targeting; Ubiquitin

Indexed keywords

ANTIBODY; ANTIGEN; ARGININE; CD8 ANTIGEN; DNA VACCINE; EPITOPE; EPOXOMICIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; LYSINE; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; VALINE; VIRUS NUCLEOPROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLUENZA VIRUS; MAMMAL CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN DEGRADATION; PROTEIN PROCESSING; T LYMPHOCYTE; TRANSGENE; TREATMENT FAILURE; UBIQUITINATION; VACCINATION; WILD TYPE; YEAST;

ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; ARTIFICIAL GENE FUSION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITOPES; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INFLUENZA A VIRUS; MICE; MICE, INBRED BALB C; NUCLEOPROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; VACCINES, DNA;

INFLUENZA VIRUS; MAMMALIA;

EID: 4444349861     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.05.035     Document Type: Article

References (56)

1. Hershko A. Ciechanover A. The ubiquitin system Annu. Rev. Biochem. 67 1998 425-479
2. Schubert U. et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes Nature 404 2000 770-774
3. Ciechanover A. Orian A. Schwartz A.L. Ubiquitin-mediated proteolysis: biological regulation via destruction Bioessays 22 2000 442-451
4. Michalek M.T. Grant E.P. Gramm C. Goldberg A.L. Rock K.L. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation Nature 363 1993 552-554
5. Rock K.L. Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides Annu. Rev. Immunol. 17 1999 739-779
6. Weissman A.M. Themes and variations on ubiquitylation Nat. Rev. Mol. Cell. Biol. 2 2001 169-178
7. Chau V. et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein Science 243 1989 1576-1583
8. Thrower J.S. Hoffman L. Rechsteiner M. Pickart C.M. Recognition of the polyubiquitin proteolytic signal EMBO J. 19 2000 94-102
9. Chung C.H. Baek S.H. Deubiquitinating enzymes: their diversity and emerging roles Biochem. Biophys. Res. Commun. 266 1999 633-640
10. Wilkinson K.D. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome Semin. Cell Dev. Biol. 11 2000 141-148
11. Kornitzer D. Ciechanover A. Modes of regulation of ubiquitin-mediated protein degradation J. Cell Physiol. 182 2000 1-11
12. Schwartz A.L. Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases Annu. Rev. Med. 50 1999 57-74
13. Barry M.A. Lai W.C. Johnston S.A. Protection against mycoplasma infection using expression-library immunization Nature 377 1995 632-635
14. Tobery T.W. Siliciano R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization J. Exp. Med. 185 1997 909-920
15. Hengel H. et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter Immunity 6 1997 623-632
16. +T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing Immunity 7 1997 791-802
17. Levitskaya J. Sharipo A. Leonchiks A. Ciechanover A. Masucci M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1 Proc. Natl. Acad. Sci. U. S. A. 94 1997 12616-12621
18. Bachmair A. Varshavsky A. The degradation signal in a short-lived protein Cell 56 1989 1019-1032
19. Bachmair A. Finley D. Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue Science 234 1986 179-186
20. Varshavsky A. Recent studies of the ubiquitin system and the N-end rule pathway Harvey Lect. 96 2000 93-116
21. Johnson E.S. Bartel B. Seufert W. Varshavsky A. Ubiquitin as a degradation signal EMBO J. 11 1992 497-505
22. Johnson E.S. Ma P.C. Ota I.M. Varshavsky A. A proteolytic pathway that recognizes ubiquitin as a degradation signal J. Biol. Chem. 270 1995 17442-17456
23. Butt T.R. Khan M.I. Marsh J. Ecker D.J. Crooke S.T. Ubiquitin-metallothionein fusion protein expression in yeast. A genetic approach for analysis of ubiquitin functions J. Biol. Chem. 263 1988 16364-16371
24. Varshavsky A. The N-end rule Cell 69 1992 725-735
25. Dantuma N.P. Heessen S. Lindsten K. Jellne M. Masucci M.G. Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal Proc. Natl. Acad. Sci. U. S. A. 97 2000 8381-8385
26. Stack J.H. Whitney M. Rodems S.M. Pollok B.A. A ubiquitin-based tagging system for controlled modulation of protein stability Nat. Biotechnol. 18 2000 1298-1302
27. Qian S.B. Ott D.E. Schubert U. Bennink J.R. Yewdell J.W. Fusion proteins with COOH-terminal ubiquitin are stable and maintain dual functionality in vivo J. Biol. Chem. 277 2002 38818-38826
28. Mulder L.C. Muesing M.A. Degradation of HIV-1 integrase by the N-end rule pathway J. Biol. Chem. 275 2000 29749-29753
29. Rodriguez F. Zhang J. Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction J. Virol. 71 1997 8497-8503
30. Delogu G. Howard A. Collins F.M. Morris S.L. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity Infect. Immun. 68 2000 3097-3102
31. Deng H. et al. A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line Cell Immunol. 215 2002 20-31
32. Vidalin O. Tanaka E. Spengler U. Trepo C. Inchauspe G. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination DNA Cell Biol. 18 1999 611-621
33. Fu T.M. et al. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens Vaccine 16 1998 1711-1717
34. Ecker D.J. et al. Increasing gene expression in yeast by fusion to ubiquitin J. Biol. Chem. 264 1989 7715-7719
35. Leachman S.A. et al. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines J. Virol. 76 2002 7616-7624
36. Ye M. Morello C.S. Spector D.H. Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge J. Virol. 76 2002 2100
37. Gonda D.K. et al. Universality and structure of the N-end rule J. Biol. Chem. 264 1989 16700-16712
38. Levy F. Johnsson N. Rumenapf T. Varshavsky A. Using ubiquitin to follow the metabolic fate of a protein Proc. Natl. Acad. Sci. U. S. A. 93 1996 4907-4912
39. Baker R.T. Varshavsky A. Inhibition of the N-end rule pathway in living cells Proc. Natl. Acad. Sci. U. S. A. 88 1991 1090-1094
40. Kessler B.M. et al. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic β-subunits Chem. Biol. 8 2001 913-929
41. Meng L. et al. Epoxomicin a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity Proc. Natl. Acad. Sci. U. S. A. 96 1999 10403-10408
42. Zeng G.C. Donegan J. Ozer H.L. Hand R. Characterization of a ts mutant of BALB/3T3 cells and correction of the defect by in vitro addition of extracts from wild-type cells Mol. Cell. Biol. 4 1984 1815-1822
43. Varshavsky A. The N-end rule: functions, mysteries, uses Proc. Natl. Acad. Sci. U. S. A. 93 1996 12142-12149
44. Suzuki T. Varshavsky A. Degradation signals in the lysine-asparagine sequence space EMBO J. 18 1999 6017-6026
45. Barry M.A. Johnston S.A. Biological features of genetic immunization Vaccine 15 1997 788-791
46. Butt T.R. et al. Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli Proc. Natl. Acad. Sci. U. S. A. 86 1989 2540-2544
47. Tang D.C. De Vit M. Johnston S.A. Genetic immunization is a simple method for eliciting an immune response Nature 356 1992 152-154
48. Fu T.M. et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes Mol. Med. 3 1997 362-371
49. Wu Y. Kipps T.J. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes J. Immunol. 159 1997 6037-6043
50. Barber L.D. Parham P. The essence of epitopes J. Exp. Med. 180 1994 1191-1194
51. Deng Y. Yewdell J.W. Eisenlohr L.C. Bennink J.R. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL J. Immunol. 158 1997 1507-1515
52. Fu T.M. Friedman A. Ulmer J.B. Liu M.A. Donnelly J.J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization J. Virol. 71 1997 2715-2721
53. Wu L. Barry M.A. Fusion protein vectors to increase protein production and evaluate the immunogenicity of genetic vaccines Mol. Ther. 2 2000 288-297
54. Singh R.A. Wu L. Barry M.A. Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine J. Immunol. 168 2002 379-391
55. Gambotto A. et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope Gene Ther. 7 2000 2036-2040
56. Belyakov I.M. et al. Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion Eur. J. Immunol. 31 2001 3557-3566